| Date Filed | Type | Description |
| 03/06/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 03/03/2023 |
SC 13D/A
| Sofinnova Capital IX reports a 0% stake in CinCor Pharma, Inc. |
| 03/01/2023 |
SC 13D/A
| Sofinnova Venture Partners X, L.P. reports a 0% stake in CinCor Pharma, Inc. |
| 02/28/2023 |
SC 13D/A
| 5AM Ventures VI, L.P. reports a 0% stake in CinCor Pharma, Inc. |
| 02/28/2023 |
4
| 5AM Partners VI, LLC (10% Owner) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Unknown transaction of 3,953,990 shares
@ $0
Unknown transaction of 487,333 shares
@ $0
Unknown transaction of 496,323 shares
@ $0 |
|
| 02/28/2023 |
SC 13D/A
| GENERAL ATLANTIC, L.P. reports a 0% stake in CinCor Pharma, Inc. |
| 02/27/2023 |
4
| HEALY JAMES (10% Owner) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Sold 6,000 shares
@ $14.32, valued at
$85.9k
Unknown transaction of 9,803 shares
@ $0
Disposed/sold 19,608 shares
@ $0
Unknown transaction of 6,073,949 shares
@ $0 |
|
| 02/27/2023 |
4
| Freeman Mason (Chief Medical Officer) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Sold 6 shares
@ $15.21, valued at
$91.3
Unknown transaction of 2,494 shares
@ $0
Disposed/sold 40,000 shares
@ $0
Unknown transaction of 100 shares
@ $0
Disposed/sold 30,178 options to buy
@ $0.92, valued at
$27.8k
Disposed/sold 145,296 options to buy
@ $5.82, valued at
$845.6k
Disposed/sold 120,380 options to buy
@ $7.62, valued at
$917.3k
|
|
| 02/24/2023 |
4
| Allison David D. (Director) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Disposed/sold 29,411 options to buy
@ $13.6, valued at
$400k
Disposed/sold 1,038 options to buy
@ $19.55, valued at
$20.3k
Disposed/sold 881 options to buy
@ $20.2, valued at
$17.8k
Disposed/sold 524 options to buy
@ $33.49, valued at
$17.5k
Disposed/sold 1,499 options to buy
@ $11.78, valued at
$17.7k
|
|
| 02/24/2023 |
4
| Ignelzi Troy A. (Director) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Disposed/sold 36,324 options to buy
@ $5.82, valued at
$211.4k
Disposed/sold 58,823 options to buy
@ $13.6, valued at
$800k
|
|
| 02/24/2023 |
4
| Kalb Michael Wayne (EVP & CFO) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Disposed/sold 202,437 shares
@ $0
Disposed/sold 77,615 options to buy
@ $30.07, valued at
$2.3M
|
|
| 02/24/2023 |
4
| Lee June (Director) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Disposed/sold 47,954 options to buy
@ $16, valued at
$767.3k
|
|
| 02/24/2023 |
4
| Pearce Catherine (COO) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Unknown transaction of 140,149 shares
@ $0
Disposed/sold 15,000 shares
@ $0
Unknown transaction of 1,500 shares
@ $0
Disposed/sold 110,136 options to buy
@ $2.55, valued at
$280.8k
Disposed/sold 13,236 restricted stock units
@ $0 |
|
| 02/24/2023 |
4
| THERO JOHN F (Director) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Disposed/sold 36,324 options to buy
@ $5.82, valued at
$211.4k
Disposed/sold 58,823 options to buy
@ $13.6, valued at
$800k
|
|
| 02/24/2023 |
4
| de Garidel Marc (CEO) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Unknown transaction of 12,500 shares
@ $0
Disposed/sold 200,000 shares
@ $0
Disposed/sold 726,483 options to buy
@ $5.82, valued at
$4.2M
Disposed/sold 601,901 options to buy
@ $7.62, valued at
$4.6M
|
|
| 02/24/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/24/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 02/24/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 02/24/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/24/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/23/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/23/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/14/2023 |
SC 13G
| PERCEPTIVE ADVISORS LLC reports a 5.9% stake in Cincor Pharma Inc. |
| 02/13/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/13/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/03/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/30/2023 |
4
| de Garidel Marc (CEO) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Granted 200,000 shares
@ $0 |
|
| 01/30/2023 |
4
| Pearce Catherine (COO) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Granted 15,000 shares
@ $0 |
|
| 01/30/2023 |
4
| Kalb Michael Wayne (EVP & CFO) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Granted 177,000 shares
@ $0 |
|
| 01/30/2023 |
4
| Freeman Mason (Chief Medical Officer) has filed a Form 4 on CinCor Pharma, Inc.|
Txns:
| Granted 40,000 shares
@ $0 |
|
| 01/23/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 01/23/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
|